Crizotinib sensitizes the erlotinib resistant HCC827GR5 cell line by influencing lysosomal function-Reference-Cited by-同舟云学术

Crizotinib sensitizes the erlotinib resistant HCC827GR5 cell line by influencing lysosomal function

Published:2020-01-20 Issue:11 Volume:235 Page:8085-8097
ISSN:0021-9541
Container-title:Journal of Cellular Physiology
language:en
Short-container-title:J Cell Physiol

Author:

Van Der Steen Nele¹²³,Keller Kaylee³,Dekker Henk³,Porcelli Letizia⁴,Honeywell Richard J.³,Van Meerloo Johan⁵,Musters René J. P.⁶,Kathmann Ietje³,Frampton Adam E.⁷⁸^ORCID,Liu Daniel S. K.⁷,Ruijtenbeek Rob⁹,Rolfo Christian¹¹⁰,Pauwels Patrick¹²,Giovannetti Elisa³¹¹^ORCID,Peters Godefridus J.³^ORCID

Affiliation:

1. Center for Oncological Research University of Antwerp Antwerp Belgium

2. Department of Pathology Antwerp University Hospital Antwerp Belgium

3. Laboratory of Medical Oncology Amsterdam Universities Medical Centers, VUmc Amsterdam The Netherlands

4. Experimental Pharmacology Laboratory IRCCS Istituto Tumori "Giovanni Paolo II" Bari Italy

5. Department of Pediatric Oncology/Hematology VUmc Amsterdam The Netherlands

6. Amsterdam University Medical Centers, VUmc Amsterdam The Netherlands

7. Division of Cancer, Department of Surgery & Cancer Imperial College London United Kingdom

8. Department of Clinical & Experimental Medicine, Faculty of Health & Medical Sciences University of Surrey Guildford United Kingdom

9. Pamgene International BV PamGene ‘s‐Hertogenbosch The Netherlands

10. Phase I‐Early Clinical Trials Unit, Oncology Department Antwerp University Hospital Antwerp Belgium

11. Cancer Pharmacology Lab, AIRC Start‐Up Unit Fondazione Pisana per la Scienza Pisa Italy

Funder

KWF Kankerbestrijding

Associazione Italiana per la Ricerca sul Cancro

Publisher

Wiley

Subject

Cell Biology,Clinical Biochemistry,Physiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcp.29463

Reference50 articles.

1. Loss of Multidrug Resistance Protein 1 Expression and Folate Efflux Activity Results in a Highly Concentrative Folate Transport in Human Leukemia Cells

2. Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma

3. Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer

4. Analysis of Drug Interactions

5. Met, metastasis, motility and more

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the therapeutic potential of a novel series of imidazothiadiazoles targeting focal adhesion kinase (FAK) for pancreatic cancer treatment: synthesis, mechanistic insights and promising antitumor and safety profile;Journal of Drug Targeting;2024-08-02

2. Exploring the therapeutic potential of a novel series of imidazothiadiazoles targeting focal adhesion kinase (FAK) for pancreatic cancer treatment: Synthesis, mechanistic Insights and promising antitumor and safety profile;2024-06-01

3. Design, synthesis and antitumor activity of 4-arylamine substituted pyrimidine derivatives as noncovalent EGFR inhibitors overcoming C797S mutation;European Journal of Medicinal Chemistry;2024-02

4. Differences in Sustained Cellular Effects of MET inhibitors Are Driven by Prolonged Target Engagement and Lysosomal Retention;Molecular Pharmacology;2022-11-18

5. Lysosome-mediated chemoresistance in acute myeloid leukemia;Cancer Drug Resistance;2022